94 results
424B5
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Prospectus supplement for primary offering
4:18pm
and obtaining reimbursement for our products from private insurance or government payors. Because of the uncertainties and risks associated … , price, the potential advantages of alternative products, the level of generic competition, and the availability of coverage and adequate reimbursement
8-K
EX-1.1
XENE
Xenon Pharmaceuticals Inc
30 Nov 23
Entry into a Material Definitive Agreement
4:15pm
.
Section 7.Reimbursement of Underwriters’ Expenses. If this Agreement is terminated by the Representatives pursuant to Section 6, Section 12(i), Section 12(v
424B5
ub5jggb7v ukjds
29 Nov 23
Prospectus supplement for primary offering
5:05pm
424B5
5q3w6 942d
23 Jun 22
Prospectus supplement for primary offering
4:09pm
8-K
EX-1.1
jxr34ooajw gnkx8ixk
23 Jun 22
Other Events
4:04pm
424B5
l7ja4
22 Jun 22
Prospectus supplement for primary offering
4:05pm
424B5
2bh6 11zrde6qf935
1 Mar 22
Prospectus supplement for primary offering
5:12pm
424B5
svnp7i0bkf j9b46qh
6 Oct 21
Prospectus supplement for primary offering
5:05pm